Anthem Biosciences Limited · NSE:ANTHEM

Anthem Biosciences — Q1 FY2026 Earnings Presentation

10 slides from Anthem Biosciences's earnings presentation, Aug 13, 2025

  1. Slide 1: Cover letter to stock exchanges on earnings call presentation

    Date: August 13, 2025 To, BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Earnings Call Presentation

  2. Slide 2: Anthem Biosciences Limited Investor Presentation

    Anthem Biosciences Limited Investor Presentation August 13, 2025

  3. Slide 3: Safe Harbour

    Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "

  4. Slide 4: Consolidated Profit & Loss Statement

    Consolidated Profit & Loss Statement Particulars (₹ Mn) Q1FY26 Q1FY25 YoY Q4FY25 QoQ FY25 Revenue from Operations 5,402 3,386 59.5% 4,832 11.8% 18,446 CRDMO 4,527 2,655 70.5% 3,923 15.4% 15,061 Specialty Ingredients 875 731 19.7% 909 -3.8% 3,385 Other Income 228 195 17.3% 141 62.2% 857 Total Revenue

  5. Slide 5: Q1FY26 Consolidated Financial Highlights

    Q1FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 5,402 39.2% 38.1% 40.0% 23.0% 24.1% 40.0% 3,386 30.0% 30.0% 20.0% 20.0% 2,143 10.0% 10.0% 0.0% 0.0% 1,404 1,358 824 Q1FY25 Q1FY26 Q1FY25 Q1FY26 Q1FY25 Q1FY26 PBT (₹ Mn)

  6. Slide 6: Strong financial performance with robust return profile for Q1FY26

    Strong financial performance with robust return profile for Q1FY26 ₹5,402 Mn 38.1% 24.1% Strong Business Q1FY26 Revenues Q1FY26 EBITDA Margin Q1FY26 PAT Margin Performance 2,149 / 1,045 324KL1 142KL Robust Technology # Employees / Scientific Staff Custom Synthesis Capacity Fermentation Capacity and

  7. Slide 7: Q1FY26 Financial Highlights

    Q1FY26 Financial Highlights  Consolidated Revenue from Operations was ₹5,402 Mn for the quarter  CRDMO business delivered ₹4,527 Mn revenues  Specialty Ingredients delivered ₹875 Mn revenues  EBITDA was ₹2,143 Mn, with EBITDA margins at 38%  PAT (Profit After Tax) was ₹1,358 Mn, with PAT margin

  8. Slide 8: Q1FY26 Business Highlights

    Q1FY26 Business Highlights Capex and Investment Highlights  Unit II (Harohalli):  Completed the expansion of 54 kL custom synthesis capacity at Unit II and commenced commercial operations  Unit III (NeoAnthem, Harohalli):  Completed and commenced operations at Unit III in a phased manner - comme

  9. Slide 9: Message from Chairman, MD and CEO

    Message from Chairman, MD and CEO “We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. Strong YoY (Year on Year) growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, ope

  10. Slide 10: Thank You

    Thank You Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit I: No.49, F1 &F2, Canara Bank Road, Unit III: 313-P,314-P, 318-P, Harohalli Bommasandra Industrial Area Phase 1, Industrial Area, Phase II, Bommasandra, Bangalore, 560 099, India Kanakapura Taluk, Ramnagar District, Har

Anthem Biosciences — Q1 FY2026 Earnings Presentation on 6ix